

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: 09/885,227
August 13, 2003
Page 2

In the Claims

Please amend the claims by replacing all prior versions, and listings, of claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1. (currently amended) A monoclonal humanized antibody directed against an epitope on glatiramer acetate ~~(Copolymer-1)~~.
2. (original) The antibody of claim 1, wherein the antibody is not cross-reactive with myelin basic protein (MBP).
3. (original) The antibody of claim 1, wherein the antibody consists essentially of IgG1.
4. (original) The antibody of claim 1, wherein the antibody does not react with mature oligodendrocytes.
5. (original) The antibody of claim 1, wherein the antibody cross-reacts with spinal cord homogenate (SCH).
6. (original) The antibody of claim 1, wherein the antibody primarily reacts with cells exhibiting a macrophage or microglial phenotype.
7. (canceled)
8. (canceled)
7. ~~9.~~ (currently amended) A F_{ab} fragment of the antibody of claim 1 that binds to an epitope on glatiramer acetate ~~(Copolymer-1)~~.
8. ~~10.~~ (currently amended) A pharmaceutical composition

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: 09/885,227
August 13, 2003
Page 3

comprising ~~an~~ the antibody of claim 1 ~~directed against an~~
~~epitope on glatiramer acetate (Copolymer 1) in an amount~~
~~effective to treat a disease associated with~~
~~demyelination of central nervous system axons~~ and a
pharmaceutically acceptable carrier.

11. (canceled)

10. ~~12.~~ (original) The pharmaceutical composition of claim ~~10~~,
wherein the antibody is not cross-reactive with myelin
basic protein (MBP). 8

11. ~~13.~~ (original) The pharmaceutical composition of claim ~~10~~,
wherein the antibody consists essentially of IgG1. 8

12. ~~14.~~ (original) The pharmaceutical composition of claim ~~10~~,
wherein the antibody does not react with mature
oligodendrocytes. 8

13. ~~15.~~ (original) The pharmaceutical composition of claim ~~10~~,
wherein the antibody cross-reacts with spinal cord
homogenate (SCH). 8

14. ~~16.~~ (original) The pharmaceutical composition of claim ~~10~~,
wherein the antibody primarily reacts with cells
exhibiting a macrophage or microglial phenotype. 8

17-53. (canceled)

9. ~~54.~~ (new) A pharmaceutical composition comprising the F_{ab}
fragment of claim ~~8~~ and a pharmaceutically acceptable
carrier. 7